Oncoinvent ASA (0RU5) is a Medical pharmaceuticals company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Oncoinvent ASA in 2026.
Next earnings date
—
Not scheduled
EPS estimate
—
Revenue estimate
—
Past earnings
No dividend history available.
Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.
Oncoinvent ASA (0RU5) last reported earnings on February 19, 2026.
Oncoinvent ASA (0RU5) is listed on London Exchange.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.